Posted in Regulatory Travere Therapeutics gains FDA approval for sparsentan in FSGS April 14, 2026 Pharmaceutical Technology Travere Therapeutics has received FDA approval for Filspari to reduce proteinuria in patients aged eight years and over with FSGS without nephrotic syndrome. RegulatoryRare DiseaseRead full story